anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A sample of 120 participants will be recruited for the study. This is a parallel randomized controlled clinical trial lasting 4 weeks, each week will consist of 5 resistance training sessions. Participants will be randomized into three groups, control, intervention or placebo. Interventions will take place after training focused on the lower limbs. The intervention group will receive a massage for 16 minutes, in the placebo group the massage cream will be applied and the participants will be asked to remain in the supine position for 16 minutes and the control group will wait the same time at rest. All participants will perform an initial assessment consisting of an initial screening questionnaire, referred morbidity index, jump test and strength test. At the beginning, during and at the end of each lower limb training, after the interventions over 96 hours, the perceptual parameters will be evaluated and the assessment of muscle tone and stiffness, elasticity, mechanical stress relaxation time and creep will be before and after the training and after the intervention. On the second day of the lower limb training on each week, the Squat Jump Test will be evaluated before, after training and after the intervention. At the end of the 4 weeks of training, the participant will perform evaluations of functional and strength outcomes. At the end of the study, the preference of the participant and the cost-benefit of the technique will also be evaluated. Participant satisfaction will be evaluated after the technique. At the end of each week and at the end of the study, a balance of outcomes will be carried out. At the end of the study, the participant will also answer a questionnaire about sensations during training to perform a qualitative analysis. Data will be described as mean and standard deviation or median and interquartile range depending on the data distribution. Data normality will be tested by the Shapiro-Wilk test. Comparisons between techniques and associations will be performed using generalized mixed models with post Bonferroni test. All analyzes will assume a significance level of p\>0.05.
Progressive relaxation exercise practice Those who agree to participate in the study will be asked to fill in the Patient and Patient Relative Form, Cheltanhams Patient Classification Scale, Caregiving Burden Scale and Meaning and Purpose of Life Scale, which include personal information and information about the patient. Relaxation exercises will be explained and demonstrated by the researcher (Funda AKTÜRK) once a day for 1 month starting from the hospitalisation to the clinic and will be played on the computer. You will be asked to perform these exercises after listening to the video (CD). Relaxation exercises are exercises based on stretching and relaxing your muscles. Before the application, in the middle of the application (15th day) and at the end of the application, all forms except the introduction form will be filled in again.
The invention discloses the technical field of antibiotic enzymes, and particularly relates to a heterozygous antibiotic enzyme for killing pathogenic bacteria of animal origin and application thereof. The hybrid antibiotic enzyme comprises a hybrid protein E1C1, wherein the hybrid protein E1C1 comprises a catalytic domain E1 shown as SEQ ID NO. 2 and a binding domain C1 shown as SEQ ID NO. 3. The invention also provides the use of a hybrid antibiotic enzyme in the manufacture of a pharmaceutical composition for controlling microbial infections, and a pharmaceutical composition comprising as an active ingredient said hybrid antibiotic enzyme. The heterozygosis antibiotic enzyme can rapidly crack common animal-derived pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus and helicobacter pylori, and can efficiently kill clinically separated common pathogenic bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, klebsiella pneumoniae and the like.
Hepatitis C recurrence after liver transplantation remains the main cause of graft loss after liver transplantation. Several strategies can be used to prevent or treat hepatitis C in the setting of liver transplantation. There are no controlled studies evaluating the efficacy and safety of antiviral treatment (using pegylated interferon and ribavirin) in liver transplant recipients. The main endpoint of this study was: 1) histological outcomes (effect of antiviral treatment on disease progression, i.e. liver fibrosis). The secondary endpoint were 1) Sustained virological response (persistent HCV-RNA clearance) and 2) Safety of pegylated interferon and ribavirin
INTRODUCTION: Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a potential tool for the management of massive gastrointestinal bleeding (MGB). This study aims to describe the experience of the use of REBOA as adjunctive therapy in patients with MGB and to evaluate its effectiveness.
METHODS: Serial cases of patients with hemorrhagic shock secondary to MGB in whom REBOA was placed were collected. Patient demographics, bleeding severity, etiology, management, and clinical outcomes were recorded.
RESULTS: Between 2017 and 2020, five cases were analyzed. All patients had a severe gastrointestinal bleeding (Glasgow Blatchford Bleeding Score range 12-17; Clinical Rockal Score range 5-9). The etiologies of MGB were perforated gastric or duodenal ulcers, esophageal varices, and vascular lesions. Systolic blood pressure increased after REBOA placement and total occlusion time was 25-60 min. REBOA provided temporary hemorrhage control in all cases and allowed additional hemostatic maneuvers to be performed. Three patients survived more than 24 h. All patients died in index hospitalization. The main cause of death was related to hemorrhagic shock.
CONCLUSIONS: Endovascular aortic occlusion can work as a bridge to further resuscitation and attempts at hemostasis in patients with MGB. REBOA provides hemodynamic support and may be used simultaneously with other hemostatic maneuvers, facilitating definitive hemorrhage control.
Provided is a composition of immunological regulation medicines. Each medicine dose unit contains interleukin 25u to 1500u, interferon 15u to 1000u, thymosin 0.5ug to 25ug, transfer factor 0.00002u to 0.0015u and hydrocortisone 30ug-150ug. Taking poultry eggs as adhesive agents, the medicines are added in the poultry eggs, are further well mixed, are dried, and are comminuted into powder, and the powder was encapsulated to finish the production. The composition of the medicines is capable of inducing and stimulating the immune response, thereby achieving the purposes of healing, disease prevention and health care. The active constituent dosage is minute in quantity, thereby being without any adverse poison deputy reaction. By observing the curative effect of abdominal smooth muscle spasm,allergic purpura, diabetes and megrim, the effect is satisfied.
Patients will drink coconut water for 7 days. After a washout period of 2 weeks, patients will then drink apple cider vinegar for 7 days.
The interaction between the immune system and the brain, crucial for blood-brain barrier integrity, is a potential factor in migraine development. Although there's evidence of a connection between immune dysregulation and migraine, a clear causal link has been lacking. To bridge this knowledge gap, we performed a two-sample Mendelian randomization (MR) analysis of 731 immune cell phenotypes to determine their causality with migraine, of which parameters included fluorescence, cell abundance, count, and morphology. Sensitivity and pleiotropy checks validated our findings. After applying a false discovery rate correction, our MR study identified 35 of 731 immune phenotypes with a significant causal link to migraine (p < 0.05). Of these, 24 showed a protective effect (inverse variance weighting : p < 0.05, odds ratio <1), and 11 were risk factors (inverse variance weighting : p < 0.05, odds ratio >1). Although limited by population sample size and potential population-specific genetic variations, our study uncovers a significant genetic link between certain immune cell markers and migraine, providing new insights into the disorder's pathophysiology. These discoveries are crucial for developing targeted biomarkers and personalized treatments. The research enhances our understanding of immune cells' role in migraine and may substantially improve patient outcomes and lessen its socio-economic impact.
FIELD: medicine. ^ SUBSTANCE: the invention relates to medicine and pharmaceutics, in particular, to creation of pharmaceutical composition in the form of suspension to prevent and treat disorders of physiological and reparative regeneration of musculoskeletal system - bone tissue and articular cartilages, in particular, to treat osteoporosis. The said pharmaceutical composition includes dimephosphon (dimethyloxobuthylphosphonilmethylate), calcium carbonate in the form of Ç£Micellate of calcium carbonate and magnesiumÇ, a polysaccharide sodium salt - sodium hyaluronate - and water with a certain ratio of the components. Offered pharmaceutical compositions have specific pharmacological expressed effect, showing reparative and regeneration effect on animal bone tissue, they do not express toxic effect with various doses and routes of experimental animals. The compositions have no irritant effect, sensibilizing action was not expressed. ^ EFFECT: the compositions can be used to prevent and to physiological and reparative regeneration of musculoskeletal system, suitable for treatment of patients additionally suffering from diabetes mellitus. ^ 2 cl, 1 ex, 1 tbl, 3 dwg
The invention discloses a matrix of a patch for external use and the patch and sleeping-aid patch made from the matrix. The matrix is prepared from part of or all of tartaric acid, potassium sorbate, sodium polyacrylate, polyvinylpolypyrrolidone, magnetic powder, glycerol, azone, polyvinyl alcohol and purified water. The patch is prepared from a plaster matrix and medicine extract, or the matrix. The sleeping-aid patch is prepared from cortex albiziae, tuber fleeceflower stems, polygala tenuifolia willd., salvia miltiorrhiza, spina date seeds, longan pulp, American ginseng, schisandra chinensis, cinnamomum cassia, root tubers of rehmannia glutinosa, sclerotia of (Poria cocos Schw.)Wolf , liquorice root leaves and peanut leaves. The matrix can generate a biological effect beneficial to organisms, improve activity of various enzymes inside organisms, improve microcirculation systems inside organisms, improve the immune function of organisms and eliminate inflammation and pain. The patch has a certain effect on relieving pain. The mammary gland proliferation patch has the effects of calming and soothing nerves, and clearing away the heart fire and relieving restlessness, can treat insomnia caused by various reasons, and is remarkable in treatment effect, safe and free of side effects.
* Cleanse surgical instruments, gloves and adjacent tissues with saline solution to reduce the adherence to the TachoSil patch. The white, inactive side of TachoSil may also adhere to surgical instruments (e.g., forceps), gloves or adjacent tissues covered with blood due to the affinity of collagen to blood. It is important to note that failure to adequately clean adjacent tissues may cause adhesions [see Warnings and Precautions (5.4)].
  * Apply the yellow, active side of the patch to the bleeding area (Fig. 2A) and hold in place with gentle pressure applied through moistened gloves or a moist pad for at least three minutes (Fig. 2B).
  * To avoid pulling the patch loose, first place a clean surgical instrument at one end of the patch before relieving the pressure (Fig. 2C). Gentle irrigation may also aid in removing the pre-moistened pad or gloved hand without removing TachoSil from the bleeding area.
  * Leave TachoSil in place once it adheres to organ tissue. Only remove unattached TachoSil patches (or part of) and replace with new patches.
  * TachoSil cannot be resterilized once removed from inner pouch. Discard unused, opened packages of TachoSil at the end of the procedure.



Figure 2: Pictures illustrating steps for method of application of TachoSil

Record patient name and TachoSil batch number every time that TachoSil is administered to a patient.
Rectocele and rectal intussusception are frequent findings in women but are often asymptomatic apart from anatomical defects, which can be seen on vaginal examination. They can be associated, however, with refractory constipation that may be best described by the terms "Outlet Obstruction" or "Obstructive Defecation Syndrome (ODS)". ODS is characterized by a symptom complex, including the feeling of incomplete evacuation associated with the need to strain excessively and for external assistance (digital, mechanical or positional maneuvers, enemas or suppositories) to aid defecation. Abdominal or rectal pain is also a common complaint. Obstetric trauma is also recognized as a contributing factor. However, none of these symptoms/factors can be singled out to be pathognomonic for this problem. ODS has a prevalence of approximately 12% in the general population.

For individuals with ODS and related intussusception/rectocele, a variety of surgical techniques including abdominal, vaginal, transanal and perineal approaches have been devised. The impact of clinical studies to evaluate these techniques has been limited by variability of results and lack of comparators. Recently, a new surgical approach was developed by an Italian surgeon, A. Longo, and has been evaluated in several European centers. These early studies and observations indicate that this new procedure may in fact provide significantly better symptom resolution in ODS patients than other available treatments, and warrants further study. The procedure is referred to as "Stapled Transanal Rectal Resection (STARR)" and this study will assess its effectiveness in a United States population.
Background: Deoxynivalenol (DON) contamination, pervasive throughout all stages of food production and processing, presents a significant threat to human health. The degradation of ferritin mediated by nuclear receptor coactivator 4 (NCOA4), termed ferritinophagy, plays a crucial role in maintaining iron homeostasis and regulating ferroptosis. Aim: This study aims to elucidate the role of ferritinophagy and ferroptosis in DON-induced liver injury. Methods: Male mice and AML12 cells were subjected to varying doses of DON, serving as in vivo and in vitro models, respectively. Protein expression was assessed by using immunofluorescence and western blot techniques. Co-immunoprecipitation was employed to investigate the protein-protein interactions. Results: Our findings demonstrate that DON triggers hepatocyte ferroptosis in a ferritinophagy-dependent manner. Specifically, DON impedes the activation of the mammalian target of rapamycin complex 1 (mTORC1) by inhibiting RAC1's binding to mTOR, thereby ultimately inducing autophagy. Concurrently, DON amplifies NCOA4's affinity for ferritin by facilitating NCOA4 phosphorylation through the ataxia-telangiectasia mutated kinase (ATM), thus promoting the autophagy-dependent degradation of ferritin. Both autophagy inhibition and NCOA4 expression suppression ameliorate DON-induced ferroptosis. Conclusion: Our study concludes that DON facilitates NCOA4-mediated ferritinophagy via the ATM-NCOA4 pathway, subsequently inducing ferroptosis in the liver.
Hypertension is significant public health problem locally as well as internationally. Untreated hypertension results in much morbidity and mortality. In Singapore, there is a significant proportion of poorly controlled hypertensives, with its attendant risks. The compliance to antihypertensive medications has been reported at about only 50%. Several pertinent factors have been brought up including dislike of oral medications, having too many medications, cost of chronic medications and side effects of medications. Several studies have also pointed out the importance of combining various components (e.g. regimen simplification, patient behavioural modification, communication and education by health professionals) in order to improve antihypertensives adherence.

This project aims to study the impact of static magnetic flux on blood pressure control. If efficacious, this may potentially provide an effective, non-invasive, non-pharmacological option for blood pressure control. In addition, the project aims to incorporate this static magnetic flux into a wearable, portable device to increase its availability and uptake. This may potentially increase compliance amongst patients who may be non-compliant to oral medications, and help reduce the attendant mortality and morbidity associated with hypertension.

In this double-blind randomized control trial, 200 participants (140 hypertensive, 60 normotensive) will be recruited. Participants will be randomized into 2:1:1 to receive the original strength magnetic device vs half strength magnetic device (half the strength of the original magnetic device) vs the sham device respectively. The half strength arm will allow us to evaluate the dose-response effect of the magnetic field. The magnetic and sham devices will be made identical in appearance and numbered for assignment purposes during the period of the trial. Study team and participants will be blinded to whether they are receiving the magnetic device or sham device.

The study participation will consist of 2 visits, an initial visit and device return visit. The participants will wear a 24hr ambulatory blood pressure (ABP) monitor for 24 hours, whereas the study device will be worn only for 8 hours. Prior to that, a blood pressure measurement will be taken at rest to confirm eligibility. Baseline ABP measurement will be taken for 3-4 hours, followed by the additional study device to be worn for the next 8 hours. Subsequently, participants will remove the study device leaving only the ABP monitor for the rest of the remaining hours. The first 3-4 hours will give an indication of the subject's baseline blood pressure. The next 8hr will give an indication of the effect of the device. The remainder 12-13hr will allow us to see the impact on blood pressure after the device is removed. The subjects will be required to complete a hardcopy questionnaire on their baseline demographics, characteristics, experience with the device, and any side effects.
This study plans to study how effective a particular psychological intervention is at reducing psychological distress for people who were diagnosed with cancer 'recurrence' since the beginning of the pandemic, having previously been diagnosed with cancer. We know that a cancer diagnosis can often result in significant psychological distress. After or during treatment for cancer, individuals often experience a 'fear of recurrence', which should it occur, often results in a state of mental anguish that is described as being more punishing than the initial diagnosis itself. Being diagnosed with a cancer recurrence diagnosis can trigger marked negative psychological symptoms, including distress, uncertainty, traumatic distress and adjustment problems, with psychological recovery from this diagnosis often being slower than that of the initial cancer diagnosis. The COVID-19 pandemic has affected these patients further, in terms of restricted access to healthcare, reduced social supports, and greater levels of treatment uncertainty. Our research team has designed a psychological intervention that is specifically aimed to help some of these issues. It's a 6-week online group intervention using a 'compassion focused therapy' approach, coupled with specialised breathing techniques to reduce bodily distress. It is being done online due to ongoing concerns around COVID but also to eliminate geographical and/or commuting barriers. It is our expectation that those receiving the psychological intervention will experience noticeable reductions in measures of psychological distress compared to those who are receiving regular treatment. It is our hope that the outcomes of this study will inform how best to help patients facing into cancer recurrence at a national level.
Chronic pain in children and adolescents is defined as pain that lasts longer than three months and is unabsorbable. Approximately 5% of the children said they were suffering from moderate to severe chronic pain, as well as impairments in their physical and psychosocial functions. Children and adolescents with chronic pain have difficulty completing activities such as walking, jogging, and participating in sports, as well as daily activities. Schoolchildren with chronic pain, for example, were shown to be five times more likely than their classmates without pain to miss school (13.9 percent vs. 2.4 percent), and it has been observed that absenteeism from school increases the likelihood of grade repeat in children with chronic pain.

Headaches affect between 57 and 82 percent of children and adolescents aged 7 to 15. It is wrong to believe that a headache with this frequency and associated concomitant conditions does not result in functional disability and limitations in everyday activities. When compared to their peers without headaches, 62 percent of children and adolescents with headaches reported more functional disability due to moderate to severe headache, limitation in daily activities, and absenteeism from school. Pain and functional incapacity caused by pain cannot be assumed to have no impact on a person's ability to participate in activities. The term "participation" refers to a person's involvement in the circumstances of his or her life. Participation in daily activities is critical for all children's healthy development, regardless of their age.

The fundamental goal of functional evaluation is to demonstrate a person's ability to function in society independently. This skill is employed in everyday activities such as personal care, social contact, housework, and recreational activities. The importance of these functions in daily life in pediatric patients, on the other hand, receives less emphasis (5). Walker and Greene (1991) developed the Functional Disability Inventory (FDI) to assess impairments in children and adolescents caused by a variety of pediatric health conditions (6). There are fifteen items in the FDI category. These tasks are used to assess how difficult it is for the youngster to walk, climb stairs, eat, do household chores, go to school, participate in sports, read and write, and watch television.

On a four-point Likert scale, (0=no issue, 4=impossible), each item is rated. With the child's own report, FDI assesses the difficulty in physical and psychological functions caused by the child's physical health. It is determined by taking into account the child's activity restrictions throughout the previous two weeks. The scale runs from 0 to 60. The total score is calculated by summing the individual item scores. A higher score indicates a higher level of disability. The purpose of this study is to see if the Turkish version of the Functional Disability Inventory (FDI) is valid and reliable in a Turkish sample of children with chronic pain.